Results 131 to 140 of about 642,659 (199)
The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 9, September 2026.ABSTRACT Rheumatoid arthritis (RA) is a common autoimmune disease, and early diagnosis is critical for effective treatment. This study aims to identify potential biomarkers related to pyroptosis through serum proteomics analysis, offering new insights for the early diagnosis of RA.
Lei Wang +10 more
wiley +1 more source
Comprehensive Assessment of PCSK9 Inhibitors for Lipid Management: Scientific Guidance Based on Drug Selection Recommendations for Chinese Medical Institutions [PDF]
Jiabao Li, Siyong Huang, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of Clinical Pharmacy,
Huang S, Li J, Chen J, Hu X
core
A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries
Frontiers in PharmacologyThe application of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represents a crucial milestone in the field of lipid-lowering therapy.
Hui-Hui Liu, Sha Li, Jian-Jun Li
doaj +1 more source
Smart Design: Integrating Artificial Intelligence and Gene Editing for Advanced mRNA Therapeutics
MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.The challenges of mRNA therapy and the application of artificial intelligence and gene editing in the field of mRNA drugs. ABSTRACT Artificial intelligence (AI) and gene editing are increasingly being applied to the design and evaluation of mRNA therapeutics.
Haixing Shi +11 more
wiley +1 more source
MedComm, Volume 7, Issue 9, September 2026.The LDL‐C/ApoB ratio, a marker of LDL size, showed significant prognostic value in statin‐treated CAD patients depending on diabetes status. A higher ratio was linked to lower cardiovascular risk only in patients with type 2 diabetes, suggesting it may be a superior biomarker for risk stratification beyond conventional lipids in this high‐risk group ...
Xiaohui Bian +6 more
wiley +1 more source
SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8753-8756, October 2026.
Salvatore Corrao +2 more
wiley +1 more source
Amino Acid Metabolism in Health and Disease
MedComm, Volume 7, Issue 9, September 2026.This graphical abstract delineates the multifaceted role of amino acid metabolism in health and disease. It illustrates how amino acids sustain physiological homeostasis across the liver, kidney, brain, heart, intestine, muscle, skeleton, and immune system.
Zhiwei Su +7 more
wiley +1 more source
Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse
, 2018 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduces low-density lipoprotein cholesterol levels and improves cardiovascular outcomes.
Virani, Salim S. +4 more
core
Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics
MedComm – Oncology, Volume 5, Issue 3, September 2026.Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley +1 more source
, 2020 Hintergrund Nach Entdeckung des Enzyms Proprotein Convertase Subtilisin-like Kexin Type 9 (PCSK9) und dessen Bedeutung für die Präsenz von LDL-Rezeptoren auf der Hepatozytenoberfläche, wurden 2015 die beiden PCSK9-Inhibitoren Evolocumab (Repatha®) und ...
Pasteiner, Martina
core